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Cocaine Esterase-Loaded Red Blood
Cells
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Veronica Termopoli4, Yingting Cai5, Fang Zheng5,6, Chang-Guo Zhan5,6,
Donald W. Landry7 and Mauro Magnani1,2*
1 Department of Biomolecular Sciences, University of Urbino, Urbino, Italy, 2 EryDel S.p.A., Milan, Italy, 3 Laboratory
of Toxicology, ASUR AV1, Pesaro, Italy, 4 Department of Pure and Applied Sciences, University of Urbino, Urbino, Italy,
5 Molecular Modeling and Biopharmaceutical Center, College of Pharmacy, University of Kentucky, Lexington, KY,
United States, 6 Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY,
United States, 7 Department of Medicine, Columbia University, New York, NY, United States
Recombinant bacterial cocaine esterase (CocE) represents a potential protein
therapeutic for cocaine use disorder treatment. Unfortunately, the native enzyme was
highly unstable and the corresponding mutagenized derivatives, RBP-8000 and E196-
301, although improving in vitro thermo-stability and in vivo half-life, were a partial
solution to the problem. For cocaine use disorder treatment, an efficient cocaine-
metabolizing enzyme with a longer residence time in circulation would be needed. We
investigated in vitro the possibility of developing red blood cells (RBCs) loaded with
RBP-8000 and E196-301 as a biocompatible system to metabolize cocaine for a longer
period of time. RBP 8000 stability within human RBCs is limited (approximately 50%
residual activity after 1 h at 37◦C) and not different as for the free enzyme, while both
free and encapsulated E196-301 showed a greater thermo-stability. By reducing cellular
glutathione content during the loading procedure, in order to preserve the disulfide
bonds opportunely created to stabilize the enzyme dimer structure, it was possible to
produce an encapsulated protein maintaining 100% stability at least after 4 h at 37◦C.
Moreover, E196-301-loaded RBCs were efficiently able to degrade cocaine in a time-
and concentration-dependent manner. The same stability results were obtained when
murine RBCs were used paving the way to preclinical investigations. Thus, our in vitro
data show that E196-301-loaded RBCs could act as efficient bioreactors in degrading
cocaine to non-toxic metabolites to be possibly considered in substance-use disorder
treatments. This approach should now be investigated in a preclinical model of cocaine
use disorder to evaluate if further protein modifications are needed to further improve
long term enzyme stability.
Keywords: cocaine use disorder, cocaine esterase, red blood cells as drug delivery system, cocaine degradation,
RBP 8000 stability, E196-301 stability
Abbreviations: BTC, butyrylthiocholine; Coc-E, cocaine esterase; GSH, reduced glutathione; Ht, haematocrit; RBCs, red
blood cells.
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INTRODUCTION
It was recently reported that cocaine was the most commonly
used illicit stimulant drug in Europe with lifetime use of 12.4
million males and 5.7 million females (European Monitoring
Centre for Drugs and Drug Addiction, 2019) and that
benzodiazepines, cocaine, or methamphetamine were present in
63% of opioid deaths during January–June 2018, among 13,631
opioid deaths in the 25 states (The United States Centers for
Disease Control and Prevention on August 30, 2019; Gladden
et al., 2019). The situation is also critical in many other areas
including South America. The Unodc World Drug Report (2019)
estimated that global illicit manufacture of cocaine reached
an all-time high of 1,976 tons in 2017, with a 25% increase
on the previous year. Substance abuse is also a significant
economic cost to society in terms of healthcare expenses, loss
of workplace productivity, justice costs, etc. Thus, cocaine abuse
is a serious problem in many countries with neither a solution
nor an approved treatment (Karila et al., 2008; Xi and Gardner,
2008). Addiction recovery programs are the main treatment
options (Source: National Institute on Drug Abuse; National
Institutes of Health; United States Department of Health and
Human Services).
As described by Schulz and Schmoldt (2003), cocaine
concentration in the blood of addicts is in the 0.5–1.0 µg/ml
range (t1/2 of approximately 0.5–1.0 h) while a comatose-
fatal dose is from 4 µg/ml. In humans, approximately 40% of
cocaine is hydrolyzed to ecgonine methyl ester, a biologically
inactive metabolite, by plasma enzyme butyrylcholinesterase
(BChE) and liver carboxyesterase-2; moreover, more cocaine is
biotransformed to benzoylecgonine via hydrolysis catalyzed by
carboxyesterase-1, and to norcocaine via oxidization catalyzed by
liver microsomal cytochrome P450 (CYP) 3A4 (Zheng and Zhan,
2012; Holmes, 2015).
Several potential therapeutics have been tested and/or are
under development, including immunotherapy (by a specific
vaccine or specific monoclonal antibodies; Carrera et al., 2004),
N-acetylcysteine (Deepmala et al., 2015), Modafinil (Kampman,
2019), and several others (Forray and Sofuoglu, 2014).
Unfortunately, drawbacks exist for most of them: engineered
bacteriophages, displaying cocaine-binding antibodies on their
surface, intranasally administered as vaccine to sequester cocaine
in the brain, could enter the periphery thus activating the
immune system; N-acetylcysteine, also if showing in a phase I
trial encouraging results in reducing cocaine related withdrawal
symptoms and craving (LaRowe et al., 2006), it was not able
to modulate basal glutamate concentrations in the nucleus
accumbens of cocaine-addicted individuals (Engeli et al., 2020);
no evidence of efficacy of Modafinil in increasing cocaine
abstinence and treatment retention rate was observed in clinical
studies (Sangroula et al., 2017). Other pharmacological strategies
for cocaine use disorder treatment thus far include the use
of glutamatergic and GABAergic agents such as topiramate
or combinations of topiramate and long-acting amphetamine.
There have been several positive trials of topiramate for
cocaine use disorder, although there have been several trials
that yield negative results as well (Johnson et al., 2013;
Kampman et al., 2013; Nuijten et al., 2014). In addition,
Topiramate also has side effects that may make it difficult
to tolerate fatigue and general mental slowing. Among the
most promising adjunct therapy for the treatment of cocaine
dependence are: (a) Cannabidiol due to its effect on cocaine
consumption, even if the evidence is limited to animal models
and further research and clinical trials are needed (Rodrigues
et al., 2020); (b) Doxazosin due to its ability in reducing
cocaine use in individuals with the ADRA1D gene polymorphism
(T1848A; Shorter et al., 2020); (c) Lorcaserin, 5-HT2CR agonist,
to reduce cocaine self-administration (Phase 1 clinical trial,
NCT02537873); (d) CI-581a and CI-581b, glutamate modulators
tested in conjunction with motivational enhancement therapy
(MET), to promote and maintain individuals’ abstinence from
cocaine (Phase III clinical trial, NCT03344419).
Despite many efforts, no medications have yet been proven to
be safe and effective for the treatment of cocaine use disorder.
Of relevance, the use of the recombinant bacterial cocaine
esterase (CocE;Narasimhan et al., 2012) was demonstrated
in vitro and in vivo to represent a potential therapeutic protein
that can be used for the degradation of cocaine to non-
toxic metabolites. Unfortunately, the native enzyme was highly
unstable (half-life about 12 min at 37◦C) and the corresponding
mutagenized derivative, although improved in vitro thermo
stability up to 6 h at 37◦C and in vivo half-life (Gao et al.,
2009), was not a solution to the problem. In fact, the reported
thermostable mutant of CocE (known as drug RBP-8000)
designed through computational modeling and simulations (Gao
et al., 2009), has been advanced to placebo controlled clinical
trial phase II for cocaine overdose treatment (Nasser et al.,
2014). The results obtained provide strong evidence supporting
the use of CocE as a pharmacotherapy for cocaine overdose
treatment. However, for cocaine use disorder treatment, a highly
efficient cocaine-metabolizing enzyme with a residence time in
circulation as long as possible would be needed. More recently,
Fang et al. (2014) designed and produced a new CocE mutant
(denoted E196-301) with additional mutations to stabilize the
dimer structure of the enzyme by cross-subunit disulfide bonds.
E196-301 showed an in vitro half-life > 100 days and protected
mice from a lethal dose of cocaine of 3 days. This is a great
advancement with respect to the state of the art in this field but
should likely be further improved in order to generate a cocaine
abuse treatment.
Although several methods are available to extend in vivo
half-life of therapeutic proteins, none surpasses the use of red
blood cells (RBCs) as carriers for therapeutic enzymes (Leuzzi
et al., 2016; Rossi et al., 2016). In fact, human RBCs circulate
for about 120 days, are removed from the blood stream only
when they are recognized as senescent and not by random
processes and, most importantly, can be loaded ex vivo with
therapeutic proteins without damaging the loaded cells that
continue to have a normal circulation in vivo (Coker et al., 2018).
Based on these premises, we have investigated the possibility
to load RBCs with both CocEs: T172R/G173Q mutagenized
protein (already designed RBP 8000) and the new E196-301
enzyme that, in addition to the T172R/G173Q modifications,
also contains the L196C/I301C mutations. The results reported
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in this paper suggest that the stability within human RBCs of
RBP 8000 is limited and not different from its free enzyme;
on the other hand, the performances of E196-301-loaded RBCs
are significantly better and in vitro they are very efficient
in degrading cocaine to non-toxic metabolites. However, the
E196-301 stability is influenced by reduced glutathione (GSH)
concentration inside the loaded cells, limiting the applicability of
the engineered cellular bioreactor. Further enzyme stabilizations
that are not redox-dependent will likely provide the final solution
to this problem.
MATERIALS AND METHODS
Mutagenized CocE
T172R/G173Q mutagenized CocE (RBP 8000), dissolved in
1% sodium phosphate buffer and showing increased stability
compared to the wild type enzyme, was provided by Columbia
University (United States). Protein concentration was 10 mg/ml
(by Bradford assay) and specific activity (SA) was estimated by
the authors to be 112 U/mg.
Cocaine esterase E196-301, containing the L196C/I301C
mutations in addition to the T172R/G173Q modifications
present in the RBP 8000, was provided by University of Kentucky
(United States). The amino acids leucine and isoleucine, replaced
with cysteine, are shown in Figure 1. These mutations produce
a pair of cross-subunit disulfide bonds (on the dimer interface)
that stabilize the dimer structure: C196a-C301b and C301a-
C196b. C196a-C301b forms a disulfide bond between C196
of subunit a (C196a) and C301 of subunit b (C301b) while
C301a-C196b forms a disulfide bond between C301 of subunit a
(C301a) and C196 of subunit b (C196b). Protein concentration
was 10 mg/ml (by Bradford assay) and SA is estimated by the
authors to be 150 U/mg.
Enzymatic Assay to Evaluate CocE
Activity
Cocaine esterase catalyzes the hydrolysis of cocaine to ecgonine
methyl ester and benzoate. For convenience, CocE activity has
been evaluated with the alternative substrate butyrylthiocholine
(BTC) since it was not hydrolyzed by the RBC acetylcholine
esterase. CocE catalyzes the hydrolysis of BTC to thiocholine and
butyrate; the rate of production of thiocholine is measured by
following the reaction between thiocholine and 5,5’-dithiobis-(2-
nitrobenzoic acid) (DTNB) at 412 nm (Beutler, 1984a).
Determination of GSH in RBCs
Intracellular GSH concentration was measured
spectrophotometrically at 412 nm by Butler’s DTNB–based
method (Beutler, 1984b).
Loading of CocE in Human RBCs
Whole blood was obtained from healthy volunteers (20 ml total
blood volume) included in the Italian blood donor registry
[registered Associazione Volontari Italiani del Sangue (AVIS)
donors] who signed an informed consent form. Blood, collected
in heparinized tubes, was provided by the Santa Maria della
Misericordia Hospital in Urbino. Briefly, CocE was loaded in
human RBCs by means of hypotonic dialysis, isotonic resealing
and re-annealing essentially as described in Magnani et al. (1988).
The dialysis procedure was carried out with different
concentrations of protein added to RBCs suspended in Hepes
buffer (154 mM NaCl, 10 mM Hepes, 5 mM glucose, pH 7.4) at
different haematocrit (Ht) to a final volume of 1 ml, as follows:
A. 2 mg of RBP 8000 (200 µl protein solution [10 mg/ml]
with SA 112 IU/mg) at 70% Ht.
B. 3 mg of RBP 8000 (300 µl protein solution [10 mg/ml]
with SA 112 IU/mg) at 60% Ht.
C. 4 mg of RBP 8000 (400 µl protein solution [10 mg/ml]
with SA 112 IU/mg at 50% Ht.
D. 3 mg of E196-301 (300 µl protein solution [10 mg/ml]
with SA 150 IU/mg) at 60% Ht (dialysis buffer with 3 mM
GSH, that is the standard buffer).
E. 3 mg of E196-301 (300 µl protein solution [10 mg/ml]
with SA 150 IU/mg) at 60% Ht (dialysis buffer without
GSH).
F. 4 mg of E196-301 (400 µl protein solution [10 mg/ml]
with SA 150 IU/mg at 50% Ht (dialysis buffer without
GSH).
G. 4 mg of E196-301 (400 µl protein solution [10 mg/ml]
with SA 150 IU/mg at 50% Ht (dialysis buffer without
GSH and with a pre-dialysis step, always without GSH).
The final osmolarity of the hypotonic solution was
70 ± 2 mOsm, measured by Osmometer Fiske Associates,
Model 210 (Norwood, MA, United States). After dialysis, the
cells reached about 92 ± 4 mOsm. To test if the removal of
intracellular GSH was beneficial for the stability of enzyme,
a condition (G) was performed by introducing a pre-dialysis
step before adding the protein. When pre-dialysis step was
performed, the human RBCs were dialyzed first alone (30 min),
then with the protein replacing the same fresh amount of dialysis
buffer. Unloaded RBCs, subjected to the same procedure without
the addition of the recombinant proteins, were used as controls.
The amount of entrapped enzyme was determined by the kinetic
assay as reported earlier on an aliquot of final loaded RBCs at
10% Ht in phosphate-buffered saline solution (PBS) containing
NaCl 137 mM, KCl 2.7 mM, Na2HPO4 10 mM, and KH2PO4
1.8 mM added with 5 mM glucose, successively diluted 1:20 in
distilled water.
Loading of CocE in Murine RBCs
Blood (about 1 ml) was collected from each anesthetized BTBR
mouse (20 ml of total blood volume) by puncture of the
retro-orbital sinus in heparinized tubes and murine RBCs were
essentially processed as previously described for human RBCs: 1,
2, and 3 mg of enzyme were added to RBC suspensions at 60%
Ht. First, murine RBCs were pre-dialyzed alone (30 min) and
then each condition was dialyzed 1 h at 4◦C vs. dialysis buffer
optimized for murine RBC loading: 15 mM NaH2PO4, 15 mM
NaHCO3, pH 7.4, 20 mM glucose, 4 mM MgCl2, and 2 mM ATP
(75 mOsm). After dialysis the cells reached about 102 mOsm.
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FIGURE 1 | Crystal structure of the cocaine esterase (CocE) dimer. Ribbon representation of the homodimeric molecule showing the side chains of the soleucine
and leucine residues that will be replaced with cysteine forming intersubunit disulfide bonds.
Subsequent steps were then carried out as described for human
cells and the amount of entrapped protein was determined.
BTBR mice come from internal breeding and sacrificed for the
maintenance of the colony. All experiments were conducted
in accordance with European legislation (2010/63/UE), with
Italian national legislation (DL26/2014) governing the use of
animals for research and with the guidelines of the National
Institutes of Health on the use and the care of laboratory animals
(Authorization n. 486/2017-PR).
In vitro Enzyme Stability
Stability of free and encapsulated CocE in human RBCs were
evaluated in vitro in the presence of PBS added with 5 mM
glucose for up to 20 h at 37◦C. Enzyme-loaded RBCs were
incubated at 10% Ht. At each time point (0, 1, 2, 3, 4, and 20 h),
residual enzyme activity was measured spectrophotometrically as
reported above (see section “Enzymatic Assay to Evaluate CocE
Activity”). Stability of CocE encapsulated in murine RBCs was
tested up to 4 h at 37◦C. Results were reported as mean ± SD of
three determinations performed in duplicate.
In vitro Cocaine Degradation by Cocaine
Esterase-Loaded RBCs
Cocaine (1 mg/ml in acetonitrile) and Cocaine-D3 (1 mg/ml in
acetonitrile) were purchased from Sigma-Aldrich (Milano) and
stored at -20◦C until use. Authorization SP/116 of 16/10/2018,
possession and scientific use of narcotic substances released to
Prof. Achille Cappiello, Laboratory of Liquid Chromatography
and Mass Spectrometry, University of Urbino.
The evaluation of cocaine degradation by CocE-loaded RBCs
in the in vitro study was performed by incubating the erythrocytes
at 37◦C for up to 2 h in PBS pH 7.2 with 5 mM glucose containing
5 µg/ml cocaine to a final 40% Ht. This cocaine concentration,
higher than that usually found in cocaine-dependent individuals,
has been selected to appreciate the efficacy of the proposed
bioreactor since at lower cocaine concentrations; CocE-loaded
RBCs could have removed it too quickly. Cocaine extraction
has been performed as follow: at planned time points (0, 2, 5,
10, 15, 30, 45, 60, 90, and 120 min) 50 µl RBC suspension
in duplicate was lysed with an equal volume of distilled water
and, after a cycle of freezing/thawing in dry ice, cold acetonitrile
containing the internal standard (Cocaine-D3 0.1 ng/µl) was
added, vortexed 1 minute for each sample, and centrifuged at
14,000 rpm at 4◦C. The supernatants were immediately frozen.
Cocaine detection has been performed by ultra performance
liquid chromatography – tandem mass spectrometry (UHPLC-
MS/MS) method internally validated in accordance with the ISS
(Istituto Superiore di Sanità), Sector guidelines and ISO 17025.
Statistical Analysis
Stability values of enzymatic activities of RBP8000 and E196-301
CocE, in free or encapsulated form, were analyzed by unpaired
t-test (Mann–Whitney test). The effectiveness of the CocE-loaded
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RBCs to metabolize cocaine across time was analyzed by one-
way ANOVA test.
RESULTS
RBP 8000 Encapsulation in Human RBCs
Three different loading procedures, using blood samples from
three different donors, were performed by varying at the
same time both the RBC hematocrit and the concentration of
enzyme during the dialysis step. It should be noticed that, to
maximize RBP8000 loading into RBCs, by decreasing RBC Ht
to 50%, a greater volume was available for free enzyme addition
thus leading to a greater amount of the encapsulated protein
(Table 1). Thus, RBP 8000-loaded human RBCs can act as cellular
bioreactors endowed with defined amounts of CocE (see A–C in
section “Loading of CocE in Human RBCs”).
TABLE 1 | RBP 8000 encapsulation in human red blood cells (RBCs) under
different experimental conditions.
Loading Samples Free CocE mg
(IU)
Dialysis
Conditions
IU CocE/ml
Packed RBCs
I a 4 (448) 50% Ht 165
b 3 (336) 60% Ht 64
c 2 (224) 70% Ht 24.5
II d 4 (448) 50% Ht 180
e 3 (336) 60% Ht 88
III f 4 (448) 50% Ht 114
g 3 (336) 60% Ht 45
Mean ± SD a-d-f 4 (448) 153 ± 35
b-e-g 3 (336) 66 ± 22
In vitro Stability of RBP 8000 Cocaine
Esterase Free and Encapsulated in
Human RBCs
Stability of free RBP8000 was tested at 37◦C in PBS containing
5 mM glucose at pH 7.2. Two different concentrations of the
enzyme were used: 0.5 ± 0.1 and 10 ± 1 U/ml. As shown in
Figure 2, residual enzyme activity after 1 h at 37◦C ranged
from 56 to 63% of the initial measured enzyme. The enzyme at
the lowest concentration (0.5 U/ml) showed a fast decay at all-
time points investigated. Thus, further studies were conducted
excluding the lowest enzyme concentration. Human RBCs loaded
with 5 ± 1 U/ml RBCs at 10% Ht and 15 ± 1.3 U/ml RBCs at
10% Ht were used. As reported in Figure 2, the RBP 8000 did not
increase its stability within the RBCs with residual activity after
1 h at 37◦C ranging from 50 to 55% of initial dose. Only about 30–
35% residual activity was still present after 4 h at 37◦C and at all-
time points, the differences in stability of the free (10 ± 1 U/ml)
vs. the RBC-loaded enzyme was not statistically different. Of note,
no enzyme activity is detected after 20 h at 37◦C in all conditions
tested. In conclusion, the limited stability of RBP 8000, already
reported (Gao et al., 2009), was confirmed and its encapsulation
in human RBCs did not counteract its fast decay.
In vitro Stability of E196-301 Cocaine
Esterase Free and Encapsulated in
Human RBCs
The in vitro stability of RBP 8000 and E196-301 at 37◦C, in
PBS at pH 7.2 was next compared. As shown in Figure 3, E196-
301 was significantly more stable than RBP 8000 under the
investigated conditions. 96% residual activity is still measurable
after 20 h at 37◦C. The figure shows the mean of duplicate results
FIGURE 2 | RBP 8000 stability. In vitro stability of free and red blood cell (RBC)-loaded RBP 8000 at 37◦C in PBS, pH 7.2. Free enzyme was tested at 0.5 ± 0.1 and
10 ± 1 IU/ml. RBC-loaded enzyme was tested at 5 ± 1 and 15 ± 1.3 IU/ml RBCs. RBC suspensions at 10% Ht were used. All experiments were in duplicate that
agree within 7.5%. Results are mean ± SD of three different experiments. Values of RBP 8000-loaded RBCs were not significantly different from control (free RBP
8000 at 10 ± 1 U/ml).
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FIGURE 3 | Stability comparison between RBP 8000 and E196-301. In vitro stability of RBP 8000 and 196-301 at 37◦C in PBS, pH 7.2. Free enzymes were tested
at 10 ± 1 and 15 ± 1 IU/ml, respectively. All experiments were in duplicate that agree within 7.5%. Results are mean ± SD of three different experiments. All values
were significantly different (p < 0.005).
FIGURE 4 | E196-301 stability in free and in red blood cell (RBC) encapsulated form. In vitro stability of free and RBC-loaded E196-301 at 37◦C in PBS, pH 7.2.
Free enzyme was tested at 15 ± 1 IU/ml, while RBC-loaded enzyme was tested at 16 ± 1 IU/ml RBCs. All experiments were in duplicate that agree within 7.5%.
Results are mean ± SD of three different experiments.
of two experiments with almost identical values. The remarkable
stability of E196-301 prompted to evaluate the enzyme stability
within human RBCs. Encapsulation of E196-301 in human RBCs
was very efficient. Starting from 3 mg of enzyme, human RBCs
containing 90 ± 5 U/ml RBCs (see D in section “Loading of
CocE in Human RBCs”), a value higher than that obtained using
RBP 8000 under identical conditions (66 ± 22 U/ml RBCs),
were developed. Unfortunately, when E196-301-loaded human
RBCs were investigated for enzyme stability at 37◦C, pH 7.2, the
enzyme showed an unexpected instability (Figure 4). A residual
activity accounting only for 48% of the initial units was observed
already after 4 h; such percentage decreased to 18% after 20 h of
incubation. Thus, E196-301 is much less stable in RBCs than in a
physiological saline solution.
Mechanisms of E196-301 Instability in
Human RBCs
The active enzyme is a dimer and possesses two disulfide bonds
between subunits that vastly stabilize the enzyme, as established
by structural studies by Fang et al. (2014). We reasoned that
since the stability of E196-301 depends on the introduction of
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FIGURE 5 | Reduced glutathione (GSH) effect on E196-301 stability. Enzyme activity has been evaluated at different times (0, 1, 2, and 3 h) after incubation at 37◦C
in a 1 ml-final volume in the absence or in the presence of different GSH concentration in the range 0.5–3 mM. Values are expressed in percentage respect to time 0.
At this time the enzyme activity was 15 IU/ml. This is representative of two different duplicate experiments that agree within 5%.
FIGURE 6 | Effect of reduced glutathione (GSH) in E196-301 stability once encapsulated in red blood cells (RBCs). In vitro stability of RBC-loaded E196-301 at 37◦C
in PBS, pH 7.2. RBC-loaded enzyme was tested at 15 ± 2 IU/ml RBCs. All experiments were in duplicate that agree within 7.5%. Results are mean ± SD of three
different experiments.
the two disulfide bonds, the reducing environment of the human
RBCs could destabilize the enzymatic dimeric structure, thus
causing a loss of stability. To verify this hypothesis, the stability
of E196-301 at 37◦C in the presence of increasing concentrations
of GSH, the most abundant reducing agent in RBCs, has been
investigated. As shown in Figure 5, E196-301 in vitro quickly
loses its stability when GSH increases from 0.5 to 3 mM, a range
of RBC physiological GSH concentrations.
Encapsulation of E196-301 in Human
RBCs Processed in the Absence and/or
Presence of GSH
The enzyme loading experiments described above were
performed in the presence of 3 mM GSH to preserve the
reducing environment of the human erythrocytes during the
encapsulation process. The removal of GSH from the buffer used
to open the pores on the RBC membrane during the enzyme
encapsulation process (see E in section “Loading of CocE in
human RBCs”), was beneficial for the stability of E196-301
(Figure 6), with residual 75% activity after 4 h at 37◦C and the
addition of 3 mM GSH during the next resealing step did not
affect this result. Thus, E196-301 in human RBCs is relatively
stable if GSH is removed from the process solutions or added
only at the final resealing step. At the same time, by performing
a pre-dialysis step of RBCs alone before the addition of the
protein to remove endogen GSH, an increase amount of active
enzyme was observed (160 vs. 53 IU E196-301/ml packed RBCs,
respectively; see G and F in section “Loading of CocE in human
RBCs”). GSH concentration in native RBCs was 3.1 ± 0.06 mM
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FIGURE 7 | Cocaine degradation. The ability of E196-301-loaded red blood cells (RBCs) to metabolize cocaine has been evaluated at different times (range 0–2 h)
after incubation at 37◦C in a 500 µl-final volume with 5 µg/ml cocaine concentration. Conditions: 0.28 IU E196-301/ml RBC suspension (blue); 0.028 IU
E196-301/ml RBC suspension (red); 0.0028 IU E196-301/ml RBC suspension (green); 0.00028 IU E196-301/ml RBC suspension (violet). This is representative of
two different duplicate experiments that agree within 5%. For the RBC condition 1:2500 the times 0, 2, 5, and 10 min are highly significant among them (****); for the
RBC 1:25000 condition each time is significantly different from the previous one up to time point 90 min (***); for the RBC condition 1:250000 a significant difference
has been observed at each time (with the exception of the time points 2, 5, and 30 min) with respect to time zero (by one-way ANOVA test, ***p < 0.001,
****p < 0.0001).
(mean of three different blood samples in duplicate ± SD). After
the enzyme encapsulation procedure, residual GSH ranged from
15 to 35% of this value (0.46 ± 0.03 to 1.1 ± 0.31) in six different
blood samples submitted to the RBC encapsulation procedure
carried on without the addition of the enzyme (sham RBCs).
E196-301-Loaded Human RBCs Are
Extremely Efficient in the Degradation of
Cocaine
The ability of E196-301 loaded RBCs to degrade extracellular
cocaine was then investigated. Cocaine (500 ng/ml) at 37◦C was
found to be quite stable under the experimental conditions used.
This low concentration was selected to appreciate also minimal
cocaine degradation. After 3 h, more than 85% (range 84–86%
in four experiments) of initial drug concentration was detectable.
The presence of RBCs didn’t affect these data, suggesting that
native RBCs don’t degrade cocaine. Instead, a suspension of
human RBCs at 40% Ht loaded with 70 ± 5 U/ml of E196-301 (see
G in section “Loading of CocE in human RBCs”) were extremely
efficient in the degradation of extracellular cocaine. No residual
cocaine was found also at the first time point of the experiment
even with 5 µg/ml of cocaine present. Thus, the investigation
has been repeated mixing E196-301 loaded human RBCs with
native (non-processed) ones from the same donor. As shown
in Figure 7 again, a dilution of enzyme-loaded RBCs in a ratio
of 1:250 with native RBCs, removed immediately cocaine from
the medium (PBS, pH 7.2, containing 5 mM glucose). Higher
dilutions provided a proportional slower degradation of cocaine
at 37◦C that was still evident at 1:25,000 dilutions. During these
experiments we have also evaluated the potential presence of
extracellular E196-301 during the cocaine consumption studies
and found to be negligible except when the CocE-loaded RBCs
were investigated at 1:250 suspensions. In this case, extracellular
E196-301 ranged from 1.3 to 2.0% (three experiments) of the
encapsulated enzyme at the end of the experiment, excluding an
eventual significant role in cocaine consumption.
E196-301 Cocaine Esterase Can Be
Efficiently Loaded Also in Murine RBCs
In order to carry out, in the future, in vivo studies on a
preclinical model of cocaine use disorder, the possibility of
producing E196-301-loaded murine RBCs was also evaluated.
E196-301 was encapsulated in murine RBCs and its stability in
physiological saline solution at 37◦C, in comparison with the free
form, was evaluated. The same loading procedure selected was
performed by a RBC pre-dialysis step, without GSH in the dialysis
buffer. Increasing amount of enzyme (1, 2, and 3 mg) has been
added to RBC suspension at final hematocrit of 60% during the
dialysis step. The results obtained are summarized in Table 2. As
shown, adding increasing amounts of protein, RBCs loaded with
increasing amounts of E196-301 have been obtained.
In vitro stability of free and encapsulated CocE has been
evaluated by incubation in PBS with 5 mM glucose for 4 h at
37◦C. Loaded murine RBC sample was investigated at 10% Ht
(mean starting activity 5, 10, and 15 IU/ml) and free protein was
tested at the concentration of 15 IU/ml. Data reported in Table 3
show that protein exhibits a high stability in the experimental
settings: after 4 h-incubation CocE entrapped in murine RBCs
kept its enzymatic activity intact.
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TABLE 2 | Results of E196-301 encapsulation in optimized loading conditions.
E196-301-Loaded
RBCs 1 mg (IU/ml
100% Ht)
E196-301-Loaded
RBCs 2 mg (IU/ml
100% Ht)
E196-301-Loaded
RBCs 3 mg (IU/ml
100% Ht)
* E196-301-Loaded
RBCs Entrapment (%)
*Cell Recovery
(%)
47 103 160 3 25
*The percentages of enzyme entrapment and cell recovery were the same for all the conditions tested (E196-301-L 1 mg, E196-301-L 2 mg and E196-301-L 3 mg).
RBCs, red blood cells.
TABLE 3 | Stability of free or red blood cell (RBC) encapsulated E196-301.
Time (h) Free E196-301
Stability (%)
E196-301-Loaded
RBCs 1 mg
Stability (%)
E196-301-Loaded
RBCs 2 mg
Stability (%)
E196-301-Loaded
RBCs 3 mg
Stability (%)
0 100 100 100 100
1 99 99 96 97
2 99 99 95 104
3 101 98 103 99
4 100 98 96 100
DISCUSSION
Cocaine abuse is a growing problem in many countries without
an obvious solution, nor an approved treatment (Karila, 2008).
Several potential therapeutics have been tested and/or are under
development including therapeutic vaccines, antagonists, and
many other approaches (Carrera et al., 2004; Xi et al., 2008; Forray
and Sofuoglu, 2014; Deepmala et al., 2015; Kampman, 2019).
Recently, the use of recombinant bacterial CoE (Narasimhan
et al., 2012) has become a relevant possibility; in fact, CocE
was demonstrated in vitro and in vivo to represent a potential
therapeutic protein for the degradation of cocaine to non-
addictive, non-toxic metabolites. However, the native enzyme
showed a high instability (half-life about 12 min at 37◦C);
the improvement in thermostability by mutagenesis and the
in vivo increased half-life (Gao et al., 2009) have represented
only a partial solution to the problem. Indeed, although the
use of CocE as a pharmacotherapy for cocaine overdose
provided good results in clinical trials, a highly efficient cocaine-
metabolizing enzyme with a longer residence time in circulation
would be preferred for cocaine use disorder treatment. More
recently, Fang et al. (2014) designed and produced a new
CocE mutant (denoted as E196-301) with additional mutations
that stabilize the dimer structure of the enzyme by cross-
subunit disulfide bonds. E196-301 showed an in vitro half-life
> 100 days and in vivo protected mice from a lethal dose
of cocaine by 3 days when administered in the PEGylated
form. Similar effects of PEGylation have also been reported
for other mutant CocEs (Narasimhan et al., 2011; Collins
et al., 2012). Indeed, PEGylation is a commonly used strategy
to extend in vivo duration of action of therapeutics protein
by reducing its immunogenicity and protecting it from the
inactivation by anti-drug antibodies. However, many clinical
studies have demonstrated that in some cases patients can also
develop anti-PEG antibodies which caused adverse reactions
and anaphylaxis (Hershfield et al., 2014; Gupta et al., 2018).
Differently, by delivering the therapeutic enzymes through RBCs,
PEGylation step can be avoided since the foreign enzyme is
confined inside the erythrocytes, allowing it to be hidden from
the immunological system and thus from any neutralizing
antibodies that may be present in circulation. Thus, although
several methods are available to extend in vivo half-life of
therapeutic proteins, none surpasses the use of RBCs (Leuzzi
et al., 2016; Rossi et al., 2016). In fact, human RBCs circulate
for about 120 days and can be loaded ex vivo with therapeutic
proteins without damaging the loaded RBCs (Coker et al.,
2018). Based on these premises, we have investigated the
possibility of loading human RBCs with both CocEs, namely
the T172R/G173Q mutagenized protein (already designed RBP
8000) and the new E196-301 enzyme that, in addition to the
T172R/G173Q modifications, also contains the L196C/I301C
mutations. The results reported in this paper confirm that the
stability within human RBCs of RBP 8000 is limited and not
different from the free enzyme and that the performances of
E196-301 loaded RBCs are significantly better and very efficient
in vitro in degrading cocaine. Unfortunately, the E196-301
stability is influenced by GSH concentration inside the loaded
cells possibly limiting the applicability of the engineered cellular
bioreactor. GSH is the main reducing agent within RBCs and
the E196-301 is stabilized by newly introduced cross-subunit
disulfide bonds. The stability of the free enzyme in vitro is
hampered by GSH and the loss of activity is concentration
dependent within the physiological GSH concentrations present
in RBCs. Furthermore, the maintenance of cellular GSH during
the encapsulation procedure by the addition of external GSH
during the loading step, promotes the loss of stability of the
loaded CocE while the removal of GSH from the dialyzing
solution, in addition to the GSH removal from RBCs by a
pre-dialysis step, improves stability and activity recovery after
the loading procedure. Through these improvements, the RBCs
loaded with E196-301 are extremely effective in catalyzing the
degradation of cocaine in a dose dependent manner, fulfilling all
the requirements for a cell-based bioreactor for the treatment of
cocaine use disorder.
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As a proof of concept, our results suggest that a single
infusion of 10 ml of a suspension of E196-301-loaded RBCs at
10% Ht (that is 1 ml packed RBCs), which exactly reproduce
the dilution of enzyme-loaded RBCs in the ratio of 1:2500
with native RBCs shown in Figure 7, could be effective in
quickly removing cocaine from circulation. Indeed, since plasma
cocaine concentration in a dependent subject could reasonably
be in the 10–1000 ng/ml range (Schulz and Schmoldt, 2003),
corresponding to 0.165–16.5 µmol/5 L blood, the infusion of
160 IU of E196-301 (see Table 2) will be extremely efficient
in a rapid and complete cocaine degradation. This conclusion
is also supported by two recent studies in which cocaine has
been administered intravenously or per os (Coe et al., 2018) or
nasal insufflation (Menzies et al., 2019) and Cmax values ranging
from 45.1 to 925 ng/ml plasma and 347.5–517.7 ng/ml plasma,
respectively, have been found. Moreover, Menzies et al. (2019)
have also in vivo demonstrated that RBC cell wall presents no
barrier to cocaine and its metabolites, thus corroborating our
in vitro studies. Furthermore, since it is known that engineered
RBCs produced for clinical use by the “Red Cell Loader” device
have a T50 survival approximately of 40 days (Coker et al.,
2018), and that the infusion of 160 IU of E196-301 by RBCs
is higher than that it is needed to quickly remove all blood
cocaine after a single dose intake, it is reasonable to assume that
a single infusion can be efficient in blood cocaine degradation
both in the case of repeated intakes over time and in the case
of higher doses intakes. Thus, efficient cell bioreactors capable
of catalyzing cocaine degradation can be produced by decreasing
the intracellular GSH content during the loading procedure.
In vitro studies confirm that these cells are stable (not shown). It
is worth noting that human RBCs can restore their physiological
level of GSH (Raftos et al., 2010). Thus, we expect a reduction
of E196-301 activity during in vivo RBCs circulation. Repeated
enzyme-loaded administrations at biweekly intervals can be
explored, instead of monthly intervals, as actually occurs for RBC
based therapies (Rossi et al., 2004; Castro et al., 2007; Chessa
et al., 2014; U. S. National Library of Medicine, 2016). As a further
alternative, enzyme stabilizations by non-redox-dependent cross-
subunit bonds will likely provide the solution to this problem.
In summary, we have proved that CocE can be encapsulated in
human and murine RBCs, offering the possibility of developing
circulating cellular bioreactors capable of an efficient cocaine
degradation. Due to the intrinsic ability of the RBCs to
restore basal GSH concentration, this approach should now be
investigated in in vivo models to define the timeframe of efficacy
for the enzyme loaded RBCs and establish the frequencies of
administration by proper pharmacokinetics studies. In case of
selected applications that require a long-lasting effect as in the
treatment of cocaine use disorder, the CocE could eventually be
modified by introducing cross subunit bonds insensitive to the
RBCs redox state. Due to the absolute medical needs and the
absence of proper treatments to diminish cocaine use disorder,
further investigations in this field are needed and welcomed. The
preliminary data collected in this paper could represent the basis
for these future studies.
DATA AVAILABILITY STATEMENT
All datasets generated in this study are included in the
article/supplementary material.
ETHICS STATEMENT
Ethical review and approval was not required for the study on
human participants in accordance with the local legislation and
institutional requirements. The patients/participants provided
their written informed consent to participate in this study.
AUTHOR CONTRIBUTIONS
All authors have contributed substantially to the present work
and have seen and approved the manuscript being submitted.
FUNDING
This work was partially supported by EryDel S.p.A. The authors
declared that this study received funding from EryDel S.p.A. The
funder was not involved in the study design, collection, analysis,
interpretation of data, the writing of this article or the decision to
submit it for publication.
ACKNOWLEDGMENTS
The authors would like to thank the staff of the Blood Transfusion
Center of the Hospital “S. Maria della Misericordia” of Urbino for
their collaboration in providing human blood.
REFERENCES
Beutler, E. (1984a). “Acetylcholinesterase”, in Red Cell Metabolism: A Manual of
Biochemical Methods (Orlando: Grune & Stratton, Inc.), 103–104.
Beutler, E. (1984b). “Reduced Glutathione (GSH)”, in Red Cell Metabolism: A
Manual of Biochemical Methods (Orlando: Grune & Stratton, Inc.), 131–134.
Carrera, M. R. A., Kaufmann, G. F., Mee, J. M., Meijler, M. M., Koob, G. F., and
Janda, K. D. (2004). Treating cocaine addiction with viruses. Proc. Natl. Acad.
Sci. U S A. 101, 10416–10421.
Castro, M., Rossi, L., Papadatou, B., Bracci, F., Knafelz, D., Ambrosini,
M. I., et al. (2007). Long-term treatment with autologous red
blood cells loaded with dexamethasone 21-phosphate in pediatric
patients affected by steroid-dependent Crohn disease. J. Pediatr.
Gastroenterol. Nutr. 44, 423–426. doi: 10.1097/mpg.0b013e318032
0667
Chessa, L., Leuzzi, V., Plebani, A., Soresina, A., Micheli, R., D’Agnano, D.,
et al. (2014). Intra-erythrocyte infusion of dexamethasone reduces neurological
symptoms in ataxia teleangiectasia patients: results of a phase 2 trial. Orphanet
J. Rare Di 9, 5–12. doi: 10.1186/1750-1172-9-5
Coe, M. A., Jufer Phipps, R. A., Cone, E. J., and Walsh, S. L. (2018). Bioavailability
and pharmacokinetics of oral cocaine in humans. J. Anal. Toxicol. 42, 285–292.
doi: 10.1093/jat/bky007
Coker, S. A., Szczepiorkowski, Z. M., Siegel, A. H., Ferrari, A., Mambrini, G.,
Anand, R., et al. (2018). A study of the pharmacokinetic properties and the
Frontiers in Physiology | www.frontiersin.org 10 September 2020 | Volume 11 | Article 573492
fphys-11-573492 September 9, 2020 Time: 9:56 # 11
Rossi et al. Cocaine Dependence Treatment by Engineered Erythrocytes
in vivo kinetics of erythrocytes loaded with dexamethasone sodium phosphate
in healthy volunteers. Transfus Me. Rev. 32, 102–110. doi: 10.1016/j.tmrv.2017.
09.001
Collins, G. T., Narasimhan, D., Cunningham, A. R., Zaks, M. E., Nichols, J., Ko,
M. C., et al. (2012). Long-lasting effects of a PEGylated mutant cocaine esterase
(CocE) on the reinforcing and discriminative stimulus effects of cocaine in rats.
Neuropsycopharmacology 37, 1092–1103. doi: 10.1038/npp.2011.226
Deepmala, D., Slattery, J., Kumar, N., Delhey, L., Berk, M., Dean, O., et al. (2015).
Clinical trials of N-acetylcysteine in psychiatry and neurology: a systematic
review. Neurosci. Biobehav. Rev. 55, 294–321. doi: 10.1016/j.neubiorev.2015.
04.015
Engeli, E. J. E., Zoelch, N., Hock, A., Nordt, C., Hulka, L. M., Kirschner, M., et al.
(2020). Impaired glutamate homeostasis in the nucleus accumbens in human
cocaine addiction. Mol Psychiatry Online ahead of print.
European Monitoring Centre for Drugs, and Drug Addiction (2019). European
Drug Report, 2019: Trends and Developments. Luxembourg: Publications Office
of the European Union.
Fang, L., Chow, K. M., Hou, S., Xue, L., Chen, X., Rodgers, D. W., et al. (2014).
Rational design, preparation, and characterization of a therapeutic enzyme
mutant with improved stability and function for cocaine detoxification. ACS
Chem. Biol. 9, 1764–1772. doi: 10.1021/cb500257s
Forray, A., and Sofuoglu, M. (2014). Future pharmacological treatments for
substance use disorders. Br. J. Clin. Pharmacol. 77, 382–400. doi: 10.1111/j.
1365-2125.2012.04474.x
Gao, D., Narasimhan, D. L., Macdonald, J., Brim, R., Ko, M. C., Landry, D. W.,
et al. (2009). Thermostable variants of cocaine esterase for long-time protection
against cocaine toxicity. Mol. Pharmacol. 75, 318–323. doi: 10.1124/mol.108.
049486
Gladden, R. M., O’Donnell, J., Mattson, C. L., and Seth, P. (2019). Changes
in opioid-involved overdose deaths by opioid type and presence of
benzodiazepines, cocaine, and methamphetamine — 25 states, July–December
2017 to January–June 2018. MMWR Morb. Mortal. Wkly. Rep. 68, 737–744.
doi: 10.15585/mmwr.mm6834a2
Gupta, S., Lau, K., Harding, C. O., Shepherd, G., Boyer, R., Atkinson, J. P., et al.
(2018). Association of immune response with efficacy and safety outcomes in
adults with phenylketonuria administered pegvaliase in phase 3 clinical trials.
EBIO Med. 37, 366–373. doi: 10.1016/j.ebiom.2018.10.038
Hershfield, M. S., Ganson, N. J., Kelly, S. J., Scarlett, E. L., Jaggers, D. A., and Sundy,
J. S. (2014). Induced and pre-existing anti-polyethylene glycol antibody in a trial
of every 3-week dosing of pegloticase for refractory gout, including in organ
transplant recipients. Arthritis Res. Ther. 16:R63.
Holmes, D. (2015). Addiction: 4 big questions. Nature 552:S63.
Johnson, B. A., Ait-Daoud, N., Wang, X. Q., Penberthy, J. K., Javors, M. A.,
Seneviratne, C., et al. (2013). Topiramate for the treatment of cocaine addiction:
a randomized clinical trial. JAMA Psychiat. 70, 1338–1346. doi: 10.1001/
jamapsychiatry.2013.2295
Kampman, K. M. (2019). The treatment of cocaine use disorder. Sci. Adv. 5,
1532–1539.
Kampman, K. M., Pettinati, H. M., Lynch, K. G., Spratt, K., Wierzbicki, M. R., and
O’Brien, C. P. (2013). A double-blind, placebo-controlled trial of topiramate
for the treatment of comorbid cocaine and alcohol dependence. Drug Alcohol
Depend 133, 94–99. doi: 10.1016/j.drugalcdep.2013.05.026
Karila, L., Gorelick, D., Weinstein, A., Noble, F., Benyamina, A., Coscas, S.,
et al. (2008). New treatments for cocaine dependence: a focused review. Int.
J. Neuropsychoph. 11, 425–438.
LaRowe, S. D., Mardikian, P., Malcolm, R., Myrick, H., Kalivas, P., McFarland, K.,
et al. (2006). Safety and tolerability of N-acetylcysteine in cocaine-dependent
individuals. Am. J. Addict. 15, 105–110. doi: 10.1080/10550490500419169
Leuzzi, V., Rossi, L., Gabucci, C., Nardecchia, F., and Magnani, M. (2016).
Erythrocyte-mediated delivery of recombinant enzymes. J. Inherit. Metab. Dis.
39, 519–530. doi: 10.1007/s10545-016-9926-0
Magnani, M., Rossi, L., Bianchi, M., Fornaini, G., Benatti, U., Guida, L., et al. (1988).
Improved metabolic properties of hexokinase-overloaded human erythrocytes.
Biochim. Biophys. Acta 972, 1–8. doi: 10.1016/0167-4889(88)90095-x
Menzies, E. L., Archer, J. R. H., Dargan, P. I., Parkin, M. C., Yamamoto, T., Wood,
D. M., et al. (2019). Detection of cocaine and its metabolites in whole blood and
plasma following a single dose, controlled administration of intranasal cocaine.
Drug Test Anal. 11, 1419–1430. doi: 10.1002/dta.2657
Narasimhan, D., Collins, G. T., Nance, M. R., Nichols, J., Edwald, E., Chan, J., et al.
(2011). Subunit stabilization and polyethylene glycolation of cocaine esterase
improves in vivo residence time. Mol. Pharmacol. 80, 1056–1065. doi: 10.1124/
mol.111.074997
Narasimhan, D., Woods, J. H., and Sunahara, R. K. (2012). Bacterial cocaine
esterase: a protein-based therapy for cocaine overdose and addiction. Future
Med. Chem. 4, 137–150. doi: 10.4155/fmc.11.194
Nasser, A. F., Fudala, P. J., Zheng, B., Liu, Y., and Heidbreder, C. (2014). A
randomized, double-blind, placebo-controlled trial of RBP-8000 in cocaine
abusers: pharmacokinetic profile of RPB-8000 and cocaine and effects of RBP-
8000 on cocaine-induced physiological effects. J. Addict. Dis. 33, 289–302. doi:
10.1080/10550887.2014.969603
Nuijten, M., Blanken, P., van den Brink, W., and Hendriks, V. (2014). Treatment of
crack-cocaine dependence with topiramate: a randomized controlled feasibility
trial in the Netherlands. Drug Alcohol Depend 138, 177–184. doi: 10.1016/j.
drugalcdep.2014.02.024
Raftos, J. E., Whillier, S., and Kuchel, P. W. (2010). Glutathione synthesis and
turnover in the human erythrocyte: alignment of a model based on detailed
enzyme kinetics with experimental data. J. Biol. Chem. 285, 23557–23567. doi:
10.1074/jbc.m109.067017
Rodrigues, L. A., Caroba, M. E. S., Taba, F. K., Filev, R., and Gallassi, A. D. (2020).
Evaluation of the potential use of cannabidiol in the treatment of cocaine use
disorder: a systematic review. Pharmacol. Biochem. Behav. 196:172982. doi:
10.1016/j.pbb.2020.172982
Rossi, L., Castro, M., D’Orio, F., Damonte, G., Serafini, S., Bigi, L., et al. (2004).
Low doses of dexamethasone constantly delivered by autologous erythrocytes
slow the progression of lung disease in cystic fibrosis patients. Blood Cells Mol.
Dis. 33, 57–63. doi: 10.1016/j.bcmd.2004.04.004
Rossi, L., Pierigè, F., Antonelli, A., Bigini, N., Gabucci, C., Peiretti, E., et al. (2016).
Engineering erythrocytes for the modulation of drugs’ and contrasting agents’
pharmacokinetics and biodistribution. Adv. Drug Deliv. Rev. 106(Pt A), 73–87.
doi: 10.1016/j.addr.2016.05.008
Sangroula, D., Motiwala, F., Wagle, B., Shah, V. C., Hagi, K., and Lippman, S.
(2017). Modafinil treatment of cocaine dependence. a systematic review and
meta-analysis. Substance Use Misuse 52, 1292–1306. doi: 10.1080/10826084.
2016.1276597
Schulz, M., and Schmoldt, A. (2003). Therapeutic and toxic blood concentrations
of more than 800 drugs and other xenobiotics. Pharmazie 58, 447–474.
Shorter, D. I., Zhang, X., Domingo, C. B., Nielsen, E. M., Kosten, T. R., and Nielsen,
D. A. (2020). Doxazosin treatment in cocaine use disorder: pharmacogenetic
response based on an alpha-1 adrenoreceptor subtype D genetic variant. Am. J.
Drug Alcohol Abuse 46, 184–193. doi: 10.1080/00952990.2019.1674864
U. S. National Library of Medicine (2016). U.S. National Library of Medecine
ClinicalTrials.gov Identifier: NCT02770807 EDS in Ataxia Telangiectasia
Patients (ATTeST). Bethesda: National Institutes of Health
Unodc World Drug Report (2019). United Nations Publication UNODC World
Drug Report 2019. Vienna: UNODC
Xi, Z. X., and Gardner, L. E. (2008). Hypothesis-driven medication discovery for
the treatment of psychostimulant addiction. Curr. Drug Abuse Rev. 1, 303–327.
doi: 10.2174/1874473710801030303
Zheng, F., and Zhan, C. G. (2012). Are pharmacokinetic approaches feasible for
treatment of cocaine addiction and overdose? Future Med. Chem. 4, 125–128.
doi: 10.4155/fmc.11.171
Conflict of Interest: MM and LR hold shares in EryDel S.p.A., a company with
interests in the technology of RBC-based drug delivery.
The remaining authors declare that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.
Copyright © 2020 Rossi, Pierigè, Agostini, Bigini, Termopoli, Cai, Zheng, Zhan,
Landry and Magnani. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) and the
copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Physiology | www.frontiersin.org 11 September 2020 | Volume 11 | Article 573492
